Skip to Content

Lorcaserin Pregnancy and Breastfeeding Warnings

Lorcaserin is also known as: Belviq, Belviq XR

Medically reviewed on Nov 13, 2017

Lorcaserin Pregnancy Warnings

Contraindicated; weight loss may result in fetal harm.

US FDA pregnancy category: X

Comments: A minimum weight gain is recommended for all pregnant women, including those who are already overweight or obese. Weight loss offers no potential benefit to a pregnant woman.

In a pre- and postnatal development study in animals, a dose approximately 44 times human exposure resulted in stillborns and lower offspring viability. All doses lowered body weight in offspring which persisted to adulthood. However, there was no evidence of teratogenicity or embryolethality; no developmental abnormalities were observed and reproductive performance was not affected at any dose. Additionally, this drug had no effects on fertility at exposures up to 29 times the human dose. There are no controlled data in human pregnancy.

US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

See references

Lorcaserin Breastfeeding Warnings

Discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Belviq (lorcaserin)." Eisai Inc, Teaneck, NJ.

References for breastfeeding information

  1. "Product Information. Belviq (lorcaserin)." Eisai Inc, Teaneck, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide